| Age | |
| Mean ± SD | 60.0 ± 11.6 |
| Median (IQR) | 62.0 (54.0–69.0) |
| Sex | |
| Men, n (%) | 4 (5) |
| Women, n (%) | 78 (95) |
| Disease duration (in years) | |
| Mean ± SD | 7.7 ± 7.1 |
| Median (IQR) | 6.0 (2.0–11.3) |
| Leroy subset, n (%) | |
| LSSc | 0 (0) |
| LcSSc | 61 (74) |
| DcSSc | 21 (26) |
| NVC pattern, n (%) | |
| Early | 29 (36) |
| Active | 24 (29) |
| Late | 24 (29) |
| Normal — Aspecific changes | 5 (6) |
| Antibodies profile*, n (%) | |
| ACA | 39 (48) |
| Anti-topo | 22 (27) |
| Anti-RNA pol III | 3 (4) |
| Pm-Scl | 1 (1) |
| Peripheral vascular therapy, n (%) “yes” | |
| Prostacyclins | 38 (46) |
| Calcium antagonists | 71 (87) |
| Endothelin receptor antagonists | 1 (1) |
| Phosphodiesterase type 5 inhibitor | 0 (0) |
| Pulmonary-vascular therapy | 5 (6) |
| Prostacyclins | 0 (0) |
| Endothelin receptor antagonists | 4 (5) |
| Phosphodiesterase type 5 inhibitor | 1 (1) |
| Lost to followup, n | 2 |
| Due to logistic reasons | 0 |
| Non-SSc-related reasons | 0 |
| SSc-related reasons | 2 |
↵* Missing for 1 patient for logistical reasons. NVC: nailfold videocapillaroscopy; IQR: interquartile range; LSSc: limited systemic sclerosis; LcSSc: limited cutaneous systemic sclerosis; DcSSc: diffuse cutaneous systemic sclerosis; ACA: anticentromere antibodies; anti-topo: antitopoisomerase; SSc: systemic sclerosis.